Literature DB >> 10621897

Progressive supranuclear palsy (Steele-Richardson-Olszewski disease).

H R Morris1, N W Wood, A J Lees.   

Abstract

Progressive supranuclear palsy is a neurodegenerative disease which affects the brainstem and basal ganglia. Patients present with disturbance of balance, a disorder of downward gaze and L-DOPA-unresponsive parkinsonism and usually develop progressive dysphagia and dysarthria leading to death from the complications of immobility and aspiration. Treatment remains largely supportive but, potentially, treatments based on cholinergic therapy may be useful. As in Alzheimer's disease, the neuronal degeneration is associated with the deposition of hyperphosphorylated tau protein as neurofibrillary tangles but there are important distinctions between the two diseases. Evidence from familial fronto-temporal dementia with parkinsonism linked to chromosome 17 suggests that tau protein deposition is a primary pathogenic event in some neurodegenerative diseases. The understanding of the mechanism of tau deposition in progressive supranuclear palsy is likely to be of importance in unravelling its aetiology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621897      PMCID: PMC1741377          DOI: 10.1136/pgmj.75.888.579

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  52 in total

1.  Eyelid movement abnormalities in progressive supranuclear palsy.

Authors:  L I Golbe; P H Davis; F E Lepore
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

2.  Characterizing swallowing abnormalities in progressive supranuclear palsy.

Authors:  I Litvan; N Sastry; B C Sonies
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

3.  Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease.

Authors:  B Dubois; B Pillon; F Legault; Y Agid; F Lhermitte
Journal:  Arch Neurol       Date:  1988-11

4.  Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  D J Brooks; V Ibanez; G V Sawle; N Quinn; A J Lees; C J Mathias; R Bannister; C D Marsden; R S Frackowiak
Journal:  Ann Neurol       Date:  1990-10       Impact factor: 10.422

5.  Physostigmine treatment of progressive supranuclear palsy.

Authors:  I Litvan; C Gomez; J R Atack; M Gillespie; A M Kask; M M Mouradian; T N Chase
Journal:  Ann Neurol       Date:  1989-09       Impact factor: 10.422

6.  Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons.

Authors:  M M Mesulam; C Geula; M A Bothwell; L B Hersh
Journal:  J Comp Neurol       Date:  1989-05-22       Impact factor: 3.215

7.  Atypical presentation of progressive supranuclear palsy.

Authors:  P H Davis; C Bergeron; D R McLachlan
Journal:  Ann Neurol       Date:  1985-04       Impact factor: 10.422

8.  Risk factors for progressive supranuclear palsy.

Authors:  P H Davis; L I Golbe; R C Duvoisin; B S Schoenberg
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

9.  The ocular motor defects in progressive supranuclear palsy.

Authors:  B T Troost; R B Daroff
Journal:  Ann Neurol       Date:  1977-11       Impact factor: 10.422

10.  Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.

Authors:  N L Foster; M S Aldrich; L Bluemlein; R F White; S Berent
Journal:  Neurology       Date:  1989-02       Impact factor: 9.910

View more
  8 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.

Authors:  Keita Kuya; Yuki Shinohara; Fuminori Miyoshi; Shinya Fujii; Yoshio Tanabe; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2016-01-16       Impact factor: 2.804

Review 3.  Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies.

Authors:  A J Degnan; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-22       Impact factor: 3.825

4.  Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy.

Authors:  Brittany N Dugger; Michael Tu; Melissa E Murray; Dennis W Dickson
Journal:  Neurosci Lett       Date:  2011-01-12       Impact factor: 3.046

5.  Exodeviated ophthalmoplegia in a patient with progressive supranuclear palsy.

Authors:  Chansok Kim; Ho Won Lee; Mee Young Park
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

6.  Saccades in progressive supranuclear palsy - maladapted, irregular, curved, and slow.

Authors:  Aasef G Shaikh; Stewart A Factor; Jorge Juncos
Journal:  Mov Disord Clin Pract       Date:  2017-08-11

7.  Progressive supranuclear palsy misdiagnosed as Parkinson's disease: a case report and review of literature.

Authors:  Lf Owolabi
Journal:  Ann Med Health Sci Res       Date:  2013-11

Review 8.  Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.

Authors:  Ruth Lamb; Jonathan D Rohrer; Andrew J Lees; Huw R Morris
Journal:  Curr Treat Options Neurol       Date:  2016-09       Impact factor: 3.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.